THE EFFECT OF AVACOPAN, A COMPLEMENT C5A RECEPTOR INHIBITOR, ON KIDNEY FUNCTION IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS WITH RENAL DISEASE

被引：0
|
作者：
Jayne, David [1 ]
Merkel, Peter [2 ]
Bekker, Pirow [3 ]
McMahon, Jeffrey [3 ]
Schall, Thomas J. [3 ]
机构：
[1] Univ Cambridge, Dept Med, Cambridge, England
[2] Hosp Univ Penn, Div Rheumatol, 3400 Spruce St, Philadelphia, PA 19104 USA
[3] ChemoCentryx Inc, Mountain View, CA USA
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2021年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
FC032
引用
收藏
页数：1
相关论文
共 50 条
  • [21] ORAL C5A RECEPTOR ANTAGONIST CCX168 IN A PHASE 2 CLINICAL TRIAL IN ANCA-ASSOCIATED RENAL VASCULITIS
    Bekker, Pirow
    Potarca, Antonia
    Dairaghi, Daniel
    Miao, Shichang
    Powers, Jay P.
    Jaen, Juan C.
    Schall, Thomas J.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 419 - 420
  • [22] PHASE 2 RANDOMISED TRIAL OF ORAL C5A RECEPTOR ANTAGONIST CCX168 IN ANCA-ASSOCIATED RENAL VASCULITIS
    Jayne, David R. W.
    Bruchfeld, Annette
    Schaier, Matthias
    Ciechanowski, Kazimierz
    Harper, Lorraine
    Jadoul, Michel
    Segelmark, Marten
    Selga, Daina
    Szombati, Istvan
    Venning, Michael
    Hamilton, Patrick
    Hugo, Christian
    Van Daele, Paul L. A.
    Viklicky, Ondrej
    Potarca, Antonia
    Schall, Thomas J.
    Bekker, Pirow
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 27 - 27
  • [23] ORAL C5A RECEPTOR ANTAGONIST CCX168 PHASE 2 CLINICAL TRIAL IN ANCA-ASSOCIATED RENAL VASCULITIS
    Jayne, D. R.
    Bruchfeld, A.
    Schaier, M.
    Ciechanowski, K.
    Harper, L.
    Jadoul, M.
    Segelmark, M.
    Selga, D.
    Szombati, I.
    Venning, M.
    Hugo, C.
    Van Daele, P. L.
    Viklicky, O.
    Potarca, A.
    Schall, T. J.
    Bekker, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 148 - 148
  • [24] Complement activation in patients with ANCA-associated vasculitis in remission
    Trattner, Rebecca
    Lordanou, Maria
    Martin, Myriam
    Segelmark, Marten
    Blom, Anna
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 110 - 110
  • [25] Analysis of Thyroid Function in ANCA-Associated Vasculitis Patients with Renal Injury
    Yu, Wenhui
    Wang, Yuelan
    Ma, Liang
    Gou, Shenju
    Fu, Ping
    JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (01):
  • [26] Safety and Efficacy of Avacopan in Patients 65 Years and Older with ANCA-Associated Vasculitis
    Rauen, Thomas
    Geetha, Duvuru
    Pagnoux, Christian
    Sattui, Sebastian E.
    Merkel, Peter A.
    Jayne, David R.
    INNERE MEDIZIN, 2024, 65 : S87 - S88
  • [27] Safety and Efficacy of Avacopan in Patients 65 Years and Older with ANCA-Associated Vasculitis
    Jayne, David
    Geetha, Duvuru
    Pagnoux, Christian
    Sattui, Sebastian
    Merkel, Peter
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1367 - 1369
  • [28] Kidney function as a predictor of relapse in ANCA-associated vasculitis
    Lwin, Khin Zar Li
    Tan, Shi Yun
    Lim, Cynthia C.
    KIDNEY INTERNATIONAL, 2025, 107 (02) : 359 - 359
  • [29] Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan
    Aqeel, Faten
    Zonozi, Reza
    Jeyabalan, Anushya
    Sauvage, Gabriel
    Niles, John L.
    Geetha, Duvuru
    RMD OPEN, 2023, 9 (03):
  • [30] Longitudinal Patterns of Renal Function in ANCA-Associated Vasculitis
    Hanberg, Jennifer
    Fu, Xiaoqing
    Cook, Claire
    Stone, John
    Choi, Hyon K.
    Wallace, Zachary
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 858 - 861
12345